New PET scan could spot liver cancer spread more clearly
NCT ID NCT05176223
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether a special PET scan using a radioactive tracer called 68Ga-PSMA can better detect advanced liver cancer that has spread. The tracer attaches to a protein found on liver cancer cells, making them visible on the scan. The study involved 29 adults with advanced liver cancer who were eligible for standard immunotherapy. The goal was to see if this imaging method improves diagnosis and helps guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gallium Ga 68 Gozetotide (68Ga-PSMA)
- What this could lead to
- If successful, this imaging method could help doctors better detect and manage advanced liver cancer, potentially leading to more personalized treatment.
- What could go wrong
- This was a small, early-phase trial with only 29 participants. The imaging technique may not prove significantly better than standard methods, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- Immunotherapy combo tested against untreatable liver cancer
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
- New drug zanzalintinib tested for advanced liver cancer